Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)

VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE

This announcement is made by Everest Medicines Limited (the "**Company**") on a voluntary basis to provide its shareholders (the "**Shareholders**") and potential investors with information in relation to the latest developments of the Company.

The board (the "**Board**") of directors (the "**Directors**") of the Company hereby announces that on 20 November 2026, the Company repurchased 739,000 shares of the Company (the "**Shares**") on the market for an aggregate consideration of approximately HK$16.1 million, representing an average price of approximately HK$21.72 per Share, pursuant to the general mandate granted to the Directors and approved by the Shareholders at the annual general meeting held on 26 June 2026. The Company may further repurchase Shares as and when appropriate in compliance with the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Law of the Cayman Islands and all applicable laws and regulations to which the Company is subject.

The Board believes that the share repurchase under the present conditions demonstrates the Company's confidence in its own business outlook and prospects and would ultimately benefit the Company and create value for the Shareholders.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By Order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 23 November 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. Xin Sun and Ms. Yue Wang as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.